Pelage Pharmaceuticals
PrivateLast Round
Series B
Oct 15, 2025
Total Funding Raised
$150.75M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Pelage Pharmaceuticals operates in Healthcare & Life Sciences and is based in Los Angeles, California. Its latest recorded funding round was a Series B round in October 2025.
Pelage Pharmaceuticals is a biotechnology company that develops regenerative medicine treatments for hair loss by reactivating dormant hair follicle stem cells.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Pelage Pharmaceuticals Comparables
Compare Pelage Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TechnoDerma Medicines Inc. | 82% | |
| Hope Medicine | 80% | |
| Veradermics Inc. | 80% |
For institutional investors. Book with your work email.
Pelage Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 15, 2025 | ||||
| Series A Extension | Aug 13, 2024 | ||||
| Series A | Feb 27, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Pelage Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GV | Series B, Series A, Series A Extension |
| Main Street Advisors | Series B, Series A, Series A Extension |
| ARCH Venture Partners | Series B |
| Visionary Ventures | Series B, Series A, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 3, 2026
Grew 21% QoQ, from 14 to 17 employees.
- Jul 20, 2026
Grew 36% QoQ from 11 to 15 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 5, 2026
Pelage Pharmaceuticals, Inc. develops a novel treatment for the more than 80 million Americans affected by hair loss, using topical small molecule PP405 designed to reactivate dormant hair follicle stem cells.
For institutional investors. Book with your work email.
Pelage Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Pelage Pharmaceuticals's valuation, stock price, and market status.
Is Pelage Pharmaceuticals a public or private company?
Pelage Pharmaceuticals is a private company.
What is the current stock price of Pelage Pharmaceuticals?
Pelage Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Pelage Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Pelage Pharmaceuticals worth (valuation)?
Valuation information for Pelage Pharmaceuticals is not publicly available.
Can I buy Pelage Pharmaceuticals stock?
Pelage Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Pelage Pharmaceuticals's last funding round?
Pelage Pharmaceuticals's most recent funding round was Series B on October 15, 2025.
Who are the main investors in Pelage Pharmaceuticals?
Key investors in Pelage Pharmaceuticals include GV, ARCH Venture Partners.
Will Pelage Pharmaceuticals IPO soon?
No public IPO plans have been announced for Pelage Pharmaceuticals.
How can I track Pelage Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Pelage Pharmaceuticals's shares on secondary markets.